Agencys contribution to the pandemic response PCWP/HCPWP joint - PowerPoint PPT Presentation

Agency’s contribution to the pandemic response PCWP/HCPWP joint meeting, 2 June 2020 Presented by: Noël Wathion, Deputy Executive Director, EMA An agency of the European Union

EMA COVID-19 Task Force Structure Communication (internal and COVID-19 Institutional external) Task Force coordination Work stream 3 Work stream 4 Work stream 1 Work stream 2 Business Continuity and Human Therapeutic Response Supply Chain Impact Resources 1 EMA status reports Classified as public by the European Medicines Agency

EMA COVID-19 structure: Mandates per entity • to ensure the Agency’s business continuity in any possible scenario following the outbreak of COVID-19 infections in Europe • to oversee work undertaken in the four areas of activities pertaining to the four workstreams Task Force • to routinely inform the Executive Board on its progress • to steer the work of the Task Force, ensuring alignment with the direction of travel of other institutions and bodies at operational and political level, in close liaison with the European Commission. Institutional Coordination • To facilitate the work of the COVID-19 Task Force • supported by teams of colleagues responsible for specific activities and deliverables. • each workstream analyse data, propose solutions and provide outcomes to the Task Force, Work where they are further reviewed and sent for final endorsement by the EXB Streams 2 EMA status reports Classified as public by the European Medicines Agency

Communication activities: External External (Network and Stakeholders): Circulation of press releases and Lines To Take (LTT) to the European Medicines Regulatory  Network Weekly circulation of outcome of EU ExSG meetings including supporting information to HMA,  EC, CMDx. Regular updates on EMA’s website on:  COVID-19 vaccines and therapeutics o Availability of medicines during the emergency o Public health advice o Guidance to companies o Press briefing on 14 May 2020  3 EMA status reports Classified as public by the European Medicines Agency

Any questions? Further information Temporary visiting address Spark building ● Orlyplein 24 ● 1043 DP Amsterdam ● The Netherlands For deliveries refer to www.ema.europa.eu/how-to-find-us Send us a question via www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 Follow us on @EMA_News Classified as public by the European Medicines Agency